TIDMMSYS
RNS Number : 9697M
Microsaic Systems plc
27 September 2021
27 September 2021
Microsaic Systems plc
("Microsaic", "Microsaic Systems" or the "Company")
Interim Results for the six months ended 30 June 2021
Microsaic Systems plc (AIM: MSYS), the developer of point of
need mass spectrometry ("MS") instruments and analytical solutions,
is pleased to announce its unaudited interim results for the six
months ended 30 June 2021. A strategic change of business model
early in 2021 has resulted in a recovery of revenues, increasing to
GBP499k in H1 2021, significantly above H1 2020 and that of H1
2019, a pre-pandemic benchmark.
Highlights
-- Unaudited r evenues of GBP499k :
o 594% increase on H1 2020 (GBP72k) and 52% improvement compared
to H1 2019 (GBP328k)
o Strongest adjusted EBITDA performance since the Company was
admitted to AIM
-- January: transformative placing which raised gross proceeds
of GBP5.5m, board changes and strategic shift away from independent
development to a commercial strategy with external partners
-- March: commercial agreement with DeepVerge plc ("DeepVerge";
AIM: DVRG), facilitating international deployment of Microsaic's
products and services in applications such as water monitoring of
chemicals and pathogens, and in support of DeepVerge's rapidly
growing Labskin division
-- May: collaboration with Swansea University to combine
real-time monitoring of environmental water using AI in determining
the link between environmental chemical pollution and human
health
-- May: Heads of Terms ("HoT") with a Chinese distributor for
the distribution of Microsaic's technology as part of a medically
licenced bed-side solution for therapeutic drug monitoring ("TDM")
in China.
-- June: initial shipments to a newly signed Chinese partner to
secure medical licence for China to deliver real-time TDM with
future recurring revenue opportunities (including service and
reagent consumables) expected in 2022
-- June: increased orders through DeepVerge sales channel under the framework agreement
-- Five key commercial hires focusing on environmental detection
of water contamination and human health markets, delivering
real-time on-site monitoring and data analytics with connected
Internet of Things ("IoT"), AI and support services
Post Period Events
-- July: First real-time monitoring demonstration of on-line
production of biotherapeutic drugs such as vaccines and anti-cancer
treatments using Process Analytical Technology within a Microsaic
micro-engineered MS solution
-- August: Heads of Terms ("HoT") signed for production of
unique point-of-care hospital bedside diagnostic unit with
manufacturing partner to support the distribution of Microsaic's
micro-engineered MS technology providing additional support for
medical device licence in China
-- August: The launch of a miniaturised mass spectrometer
platform, achieving triple quadrupole ("Triple Quad") limits of
detection for real-time monitoring and identification of organic
chemicals in water and soil, a first for MS technology delivering
regulatory-grade testing methods in the field
-- September: Signing of a full agreement with a Chinese partner
Jiangsu Henzhihe Technologies Co. Ltd ("HZH"), providing a forward
manufacturing and service support centre for distributors in China.
HZH will initially support the Chinese distributor (RNS 4th May
2021) for point of need TDM, and securing a medical licence to ship
products in China into this (and other) markets globally
Ongoing commercial developments
-- Disruptive low-cost and mobile system to detect organic
chemicals in water and wastewater adapted for in-field
deployment
-- Detection of volatile contaminants in water, with product
demonstration expected in H2 of this year. This significantly
expands the reach of applications with mobile capability for
environmental regulatory authorities
-- Multiple collaboration projects, including in-surgery cancer
diagnostics, with the aim to secure commercial supply agreements
with the potential to revolutionise operating theatre surgical
oncology interventions
Outlook
-- The Board anticipates the sales momentum of H1 to continue in
H2 based on its sales pipeline. Potential collaborations and trials
with DeepVerge may lead to significant opportunities in
environmental water detection
-- During the second half of 2021 the Board expects full
agreements to be signed with its Chinese Partners for the assembly,
distribution and servicing of its product in China, ahead of
achieving a medical device licence in China for therapeutic drug
monitoring in 2022
-- Furthermore, in H2 , Microsaic intends to appoint a contract
research organisation ("CRO") to undertake cell line work in
bioreactors before placing its bioprocessing technology and
services with end-user biopharma for beta trials, ahead of expected
commercialisation in 2022
-- The Company expects to launch a new detection platform in H2,
targeting a wider range of chemical contaminants in water. This
will further augment the combined chemical/pathogen detection
capabilities between DeepVerge and Microsaic
Glenn Tracey, CEO of Microsaic Systems plc, commented:
" I am thrilled to report this transformational performance for
the first half of 2021, following the effects the COVID-19 lockdown
had on our customers, suppliers and employees throughout 2020 and
the operational and financial strain this placed on the Company.
The new commercial strategy of collaborating, partnering and
revenue sharing is moving the Company away from equipment-only
sales. Microsaic is now focused on offering integrated real-time
data analytics with AI alongside our mass spectrometry hardware,
providing complete, value-adding solutions such as in-field
environmental testing and on-site human diagnostics. The change in
strategy and business model has already opened up new market
opportunities and applications for our differentiated technology
solutions, and demonstrated solid evidence of sales growth which is
expected to continue into H2.
I am also delighted to have signed our partners HZH, which
represents a major expansion of our global footprint as we continue
to bring on point of need technical solutions in the near
term."
Enquiries:
Microsaic Systems plc
Glenn Tracey, CEO +44 (0)1483
Bevan Metcalf, FD 751 577
Singer Capital Markets (Nominated Adviser & Joint
Broker) +44 (0)20 7496
Aubrey Powell / Tom Salvesen / George Tzimas 3000
Turner Pope Investments (TPI) Limited (Joint
Broker) +44 (0)20 3657
Andy Thacker / James Pope 0050
About Microsaic Systems
Microsaic listed on AIM in 2011 to develop and commercialise
micro-engineering chip-based mass spectrometry equipment. Having
invested GBP30m (before the last fundraising) over the last 20
years before and after the IPO, Microsaic has a robust patent
portfolio in cutting-edge technology purpose built for "Industry
4.0" which enables analytical detection and characterisation at the
point-of-need, whether within a human health environment,
conventional laboratory setting, or within a bioprocessing facility
for continuous mass spectrometer detection and monitoring of data
at any step in the process workflow.
Microsaic's products and solutions are commercially available
through global markets via a network of regional and local
partners, targeting its core laboratory, manufacturing and
point-of-need applications.
CEO Statement
Performance
Revenues were GBP499k for the period , an impressive 594 per
cent. increase over H1 2020 (GBP72k) and 52 per cent. over H1 2019
(GBP328k). After a transformative placing , raising gross proceeds
of GBP5. 5m , and board changes, the Company immediately
implemented changes to its market and business strategy.
Market Strategy
The Company has focused on two key markets, reflecting its
commitment to solving real world problems affecting our Health and
Environment using our unique screening and monitoring platforms,
incorporating MS detection technology, software, and services to
end users.
Human Health
Microsaic's products and services span several markets,
characterising the evolution of human health from drug discovery,
through to manufacturing, quality control and therapeutic
monitoring.
Bioprocessing and manufacturing
The Company has identified a significant market for in-situ
analysis of small and large molecules, particularly in upstream
bioprocessing. Applications identified to date include monitoring
the quality of incoming feedstocks, and identification of target
proteins (biologic drugs) and their metabolites. The Board believes
that Microsaic's technology, integrated into existing workflows,
will provide customers with significant cost savings, but more
importantly will provide additional data not usually seen by
traditional optical and assay-based methods during the
bio-manufacturing process. Such an approach could greatly assist
biologics manufacturers to meet increasing demands from regulators
to provide more data, sooner, in the development, scale-up and
manufacturing processes.
Microsaic announced on 2 July, that it had interfaced its
micro-engineered and fully portable MS detector with a bioreactor
and autosampler, coupled with process control software, to provide
continuous, real-time analysis of the biomanufacturing process,
including the provision of additional data analytics for quality
monitoring and assurance.
Biopharmaceuticals is a well-established and rapidly growing
sector (currently valued at circa $200 billion (1) ), which faces
significant challenges around process robustness. This is
particularly apparent within upstream processing, which relies on
fundamental biology and carries inherent product variability risks.
Point-of-need MS would provide timely and critical safety and
quality assurance, as adverse effects would be identified earlier
in the process and mitigated upstream.
The analytical instrumentation market in upstream bioprocessing
alone was projected to be worth circa $390 million in 2020 (2) .
The Company believes that its compact, easy-to-use, MS technology
is well-positioned to access a share of this market, working with
bioprocessing instrument providers and end-users in
biopharmaceutical manufacturing alike.
Additionally, Microsaic's technology has been interfaced with
more traditional pharmaceutical manufacturing, with accounts such
as Merck, Corning and Samsung.
Therapeutic Drug Monitoring - China Opportunity
In May, Microsaic announced the signing of non-binding HoT with
a Chinese partner (the "Partner"). The HoT describe the
in-principle agreement for the parties to collaborate to supply and
market Microsaic's micro-engineered MS technology for use within a
point of care medical device monitoring system for hospital
diagnostics in the Chinese market. In 2019, there were 33,000
hospitals registered in China, with 7.9 million beds(3) .
Under the HoT, the first application will be in monitoring
psychiatric therapeutic drugs, with further monitoring applications
to follow. Subject to completion of a final agreement with the
Partner, Microsaic expects to generate two streams of revenue, from
both the initial sale of monitoring systems and the subsequent
recurring revenue-share from the supply of reagents and consumables
used for monitoring.
Both parties will negotiate and agree the terms of the proposed
assembly and sale of the monitoring equipment. The Company
anticipates that the requisite medical device licence will be
secured during 2022, although Microsaic's technology is expected to
have production capability in China later this year, which will be
in support of product testing and validation for Chinese regulatory
approval.
In August, HoT were signed with a manufacturing partner, to
support the production and distribution of Microsaic's
micro-engineered MS technology and support the medical device
licence referred to above in China.
Microsaic will seek similar applications in healthcare markets
across North America and Europe.
Environmental Health
In May, Microsaic announced a collaboration with Swansea
University Medical School, utilising Microsaic's miniature mass
spectrometry equipment, to develop a monitoring platform capable of
measuring per- and polyfluoroalkyl substances ("PFAS", also known
as 'forever chemicals') at source and within a laboratory setting.
Solidifying the link between environmental and human health, this
will be used to establish the health impacts of the broader range
of PFAS pollutants. The detection platform will combine
environmental sample preparation and epigenetic approaches with
Microsaic's miniature mass spectrometer. Through partnership with
stakeholders in the environmental sector, this collaboration is
designed to better inform pollution remediation, improve management
processes for reduced emission and promote safer handling of PFAS
chemicals.
PFAS are pollutants of increasing concern, known as 'forever
chemicals' given their environmental persistence following use as
protective, non-stick, and fire-retardant coatings within
electronics, textiles, cleaning agents and cookware. There is a
shortage of environmental testing globally yet initial human
epigenetic studies show reproductive, developmental, liver, kidney
and immunological effects(5,6,7) from skin contact or contaminated
food or water, meaning there is an increasing need to monitor these
pollutants. Furthermore, given there are conflicting, unresolved
and unclear accounts of the epigenetic mechanisms of specific PFAS
(e.g. DNA methylation with PFOS and PFOA)(7,8) , questions remain
as to how epigenetic changes occur across the chemical range and
for mixtures of PFAS pollutants.
Environmental pollution has been strongly linked to adverse
human health outcomes, prompting growing research activity to
determine how this leads to disease. Given the breadth of chemicals
used in everyday life and their resistance to environmental
breakdown, the risk of pollution following release via production,
use, residues in goods, ineffective wastewater remediation, and/or
leachate from landfill is significant.
In August this year, Microsaic launched a miniaturised mass
spectrometer platform, providing fully integrated front-end
solutions, and using AI software upgrades from DeepVerge, to
achieve triple quad limits of detection for real-time monitoring
and identification of organic chemicals in water and soil. Triple
Quad limits of detection mean increased sensitivity and
specificity, which allows detection and quantification at lower
limits than conventional single quad mass spectroscopy.
In collaboration with DeepVerge's environmental division, which
has implemented real-time services for the automated detection and
identification of metals and pathogens, Microsaic now augments this
offering with automated real-time detection and expert analysis of
dangerous organic chemicals in water and soil.
The detection capability for a variety of contaminants and toxic
"bad actors" adds:
-- Organic chemical expertise and detection of Chemicals of
Emerging Concern ("CECs"), currently unregulated and unmeasured,
with the European Chemical Agency in 2020 identifying 290 chemical
candidates for regulatory action by the European Commission(4)
-- Significant augmentation to the revenue channels of both
Microsaic and DeepVerge without re-engineering their business
infrastructure
-- Screening - project deployment (e.g. site remediation, clean
up, chronic or acute spills), mobile laboratory/van etc.
-- Monitoring - site surveillance (e.g. waste water treatment
plants, sites of special interest). Substantial value-add to
customers, as the retrofit or standalone integration of our
combined solutions, including high-tech hardware, software and AI,
adds:
-- Unified data handling
-- Unified/integrated sampling strategies
-- Unified front-end to customers installations and
collaborations
-- Powerful and accurate analysis of aggregated data with AI
delivering the ability to detect an array of targets in a single
platform and with predictive alert capability
The new portable Microsaic platform, with Triple Quad limits of
detection is unique, bringing laboratory quality performance to the
front-line, at a fraction of the cost and up to 90% smaller than
traditional Triple Quad mass spectrometers, reducing workflows and
allowing manual, or automated decision making in real-time.
Diversified Industries
Microsaic serves selected additional markets where there is a
strong "real-world" problem to solve. Examples of markets where our
technology is applied include food safety, food contamination and
counterfeiting, agrichemical production and explosives
detection.
Business Strategy
Following changes to the Board in January this year, Microsaic
undertook an immediate strategic review of its markets, business
model and operations. With the Company being ideally placed for
front-line or on-line screening and monitoring, the Board
recognised a clear advantage in combining Microsaic's unique
chip-based detection technology with AI capabilities and
application software, for multiple/key account installations where
real-world problems needed immediate solutions. Such examples are
real-time environmental monitoring, high-value manufacturing of
therapeutics and real-time drug monitoring.
In March of this year, Microsaic signed a non-binding framework
agreement with DeepVerge Plc. This agreement incorporated several
facets:
-- Utilising DeepVerge's global sales channel, particularly in environmental water monitoring
-- Collaborating to combine both companies' technologies and
integrating with software, to deliver systems that utilise the
capabilities of Microsaic's environmental chemical detection with
DeepVerge's environmental pathogen detection
-- Creating a joint facility at DeepVerge's site in York, to
accelerate collaboration and acting as a customer demonstration
facility
Microsaic had historically operated a capital sale model. This
period has seen Microsaic transitioning to an annuity model, for
its hardware, software and value-adding services.
Outlook
The Board anticipates the sales momentum of H1 to continue in H2
based on its sales pipeline. Potential collaborations and trials
with DeepVerge may lead to significant opportunities in
environmental water detection.
During the second half of 2021 the Board expects full agreements
to be signed with its Chinese Partners for the assembly,
distribution and servicing of its product in China, ahead of
achieving a medical device licence in China for therapeutic drug
monitoring in 2022.
Furthermore, in H2 , Microsaic intends to appoint a contract
research organisation ("CRO") to undertake cell line work in
bioreactors before placing its bioprocessing technology and
services with end-user biopharma for beta trials, ahead of expected
commercialisation in 2022.
The Company expects to launch a new detection platform in H2,
targeting a wider range of chemical contaminants in water. This
will further augment the combined chemical/pathogen detection
capabilities between DeepVerge and Microsaic.
Glenn Tracey
CEO
27 September 2021
(1) 2020 Global Life Sciences Outlook(,) Deloitte
(2) Report on upstream bioprocessing analytical instrumentation,
TDA consultants 2019
(3) China Hospital Industry Report, 2019-2025
(4) https://echa.europa.eu/-/nearly-300-chemicals-identified-as-candidates-for-regulatory-action
(5) EPA,
https://www.epa.gov/pfas/basic-information-pfas#difference
(6) Toxicology Department CRCE, PHE 2009 Version 1 , PFOS and
PFOA: General Informatio n
(7) Kim, S,.Thapar, I., Brooks, B. W., Epigenetic changes by
per- and polyfluoroalkyl substances (PFAS). 2021. Env. Pol. 279: p.
116929.
(8) Kingsley, S.L., Kelsey, K.T., Butler, R., Chen, A., Eliot,
M.N., Romano, M.E., et al., 2017. Maternal serum PFOA concentration
and DNA methylation in cord blood: a pilot study. Environ. Res.
158, 174e178. etc
Financial Review
Statement of Comprehensive Income:
In H1 2021, total revenues of GBP499,285 were 594 per cent. or
GBP427,293 above H1 2020 (GBP71,992) showing a significant recovery
from 2020 which was adversely affected by COVID-19.
Product revenues increased by GBP367,474 (H1 2020: Nil) while
consumables and spares revenues increased by 79 per cent. and
service and support income by 133 per cent.
Gross margin in H1 2021 was 34.3 per cent. This was below the
margin achieved in H1 2020 (53.2 per cent.) due to the change in
product mix with lower margins on product revenues.
Other operating income in H1 2021 of GBP47,033 represents
furlough grant income for January 2021 and development income.
Other operating income in H1 2020 was restated (see note 4) to
include furlough grant income of GBP40,324 for the period April to
June 2020.
Operating expenses of GBP1,216,702 are GBP308,286 lower than
prior year (H1 2020 Restated: GBP1,524,988). Operating expenses in
H1 2020 were restated to exclude the furlough grant income of
GBP40,324 as mentioned above. The reduction in operating expenses
included staff related costs which reduced by GBP81,731 and
includes payroll (GBP56,688), travel (GBP51,835), and other staff
costs (GBP6,308) but off-set by an increase in recruitment
(GBP33,100). Other reductions included R&D contractors
(GBP127,142), R&D materials and warranty (GBP65,275), premises
(GBP25,567), and marketing and IP (GBP31,050). Other expenses
increased by GBP22,479 which included an increase in exceptional
costs relating to advisers and legal costs.
The loss from operations, before share-based payments ("SBP") of
GBP998,316 is 31 per cent. lower than the loss recorded in H1 2020
(GBP1,446,369).
EBITDA Adjusted Loss is a key performance indicator of the
Company's profitability. The EBITDA Adjusted Loss in H1 2021 was
GBP838,804 compared with GBP1,300,902 in H1 2020, an improvement of
GBP462,098. Note 7 details the difference between EBITDA Adjusted
Loss and Comprehensive Loss for the period.
The SBP charge in H1 of GBP1,110,038 (2020: GBP31,418) is
significantly above the prior year. During the period 750 million
options/warrants awarded to Directors and a consultant vested
within 30 days of their grant after meeting the performance
criterion leading to a charge of GBP1,125,283. Options awarded to
staff vest over two years and incurred a SBP charge of GBP114,774.
These charges were partly off-set by the cancelation of existing
options of GBP130,019.
The comprehensive loss of GBP2,106,925 is 42.4 per cent. higher
than H1 2020 (GBP1,479,949) with the reduction in the loss from
operations being off-set by the increase in the SBP charge. The
basic loss per share of 0.042p is significantly below last year (H1
2020: 0.32p per share) due to the issue of 5.62 billion ordinary
shares at the time of the fundraise in February 2021.
Statement of Financial Position:
Total non-current assets of GBP204,976 are GBP42,336 below the
December balance. This was mainly due to a reduction of in the
right of use assets of GBP34,367, representing the depreciation
charge in the period.
Total current assets of GBP5,603,025 are GBP4,243,928 above the
December balance. This is mainly due to a higher cash balance at
the period end of GBP4,483,252 (up GBP4,086,183) following the
GBP5.5 million (before expenses) fundraise in February 2021.
Inventories of GBP377,156 are GBP192,433 below the December level
due to the higher revenues in H1 2021. Trade receivables of
GBP348,722 are GBP240,193 above the December balance mainly due to
higher revenues in June 2021. Other receivables of GBP206,304 are
GBP82,919 above December due mainly to the higher level of
prepayments. The corporation tax receivable of GBP218,568 was
outstanding at 30 June 2021 and received in August 2021 post period
end.
Total assets of GBP5,808,001 are GBP4,201,592 above December
(GBP1,606,409), mainly due to the higher cash balance as explained
above.
Total equity of GBP5,449,233 is GBP4,206,253 above December 2020
(GBP1,242,980). The main movements during the period were the net
proceeds from the fundraise of GBP5,083,140, shares issued in
exchange for services of GBP120,000 plus the SBP charge share of
GBP1,110,038 off-set by the comprehensive loss of GBP2,106,925.
Current liabilities of GBP261,489 are GBP23,192 above the
December 2020 balance. Trade and other payables of GBP245,346
increased by GBP59,419 (see note 14), partly off-set by the lease
liability which reduced by GBP36,227 to GBP16,143.
Total non-current liabilities of GBP97,279 are GBP27,853 below
December 2020. Provisions decreased by GBP26,756 due to a lower
warranty provision.
Statement of Cash Flows:
Cash used in operations in H1 2021 of GBP924,994 is GBP395,796
lower than H1 2020, mainly due to the reduction in the
comprehensive loss after the adjustment for non-cash items.
The net cash used in operating activities of GBP924,994 was only
GBP74,211 below H1 2020 as the corporation tax receivable
(GBP218,568) was not received by the period end whereas in H1 2020
it was received in May 2020.
Net cash used in investing activities in H1 2021 of GBP50,832
(H1 2020: GBP36,245) increased by GBP14,587 over last year. The
main movements were an increase in the purchases of property, plant
and equipment of GBP893, off-set by a decrease in the purchases of
intangibles of GBP4,053 and lower interest income, of
GBP17,747.
Net cash from financing activities amounted to GBP5,062,009
which includes net cash raised from the fundraising of
GBP5,083,140, furlough grant income of GBP17,748, off-set by
payments for lease commitments of GBP38,879.
The net increase in cash at the period end was GBP4,086,183
giving a closing cash balance of GBP4,483,252 at 30 June 2021.
Going Concern:
Following the successful fundraise in February 2021 and having
considered the plans and prospects of the business, the Board of
Directors believes that the Company has enough cash to cover its
anticipated working capital requirements for the next 12 months.
Therefore, the Directors have adopted the going concern basis of
reporting in preparing the financial statements.
Bevan Metcalf
Finance Director and Company Secretary
27 September 2021
STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED)
FOR THE SIX MONTHSED 30 JUNE 2021
Notes 6 months 6 months Year to
to 30 June to 30 June 31 December
2021 2020 2020
Unaudited Unaudited Audited
RESTATED
GBP GBP GBP
-------------------------------------------- ------- ------------- ------------- --------------
Revenue 5 499,285 71,992 198,258
Cost of sales (327,932) (33,697) (98,348)
-------------------------------------------- ------- ------------- ------------- --------------
Gross profit 171,353 38,295 99,910
Other operating income 47,033 40,324 96,626
Research and development expenses (312,755) (498,817) (777,597)
Professional fees - Corporate transactions (65,789) (39,036) (149,364)
Other operating expenses (838,158) (987,135) (1,801,321)
-------------------------------------------- ------- ------------- ------------- --------------
Total operating expenses (1,216,702) (1,524,988) (2,728,282)
-------------------------------------------- ------- ------------- ------------- --------------
Loss from operations before share-based
payments (998,316) (1,446,369) (2,531,746)
-------------------------------------------- ------- ------------- ------------- --------------
Share-based payments (1,110,038) (31,418) (52,241)
-------------------------------------------- ------- ------------- ------------- --------------
Loss from operations after share-based
payments (2,108,354) (1,477,787) (2,583,987)
Financial cost (1,554) (5,664) (10,775)
Finance income 2,983 4,359 4,393
-------------------------------------------- ------- ------------- ------------- --------------
Loss before tax (2,106,925) (1,479,092) (2,590,369)
Tax on loss on ordinary activities - (857) 217,711
-------------------------------------------- ------- ------------- ------------- --------------
Total comprehensive loss for the
period (2,106,925) (1,479,949) (2,372,658)
-------------------------------------------- ------- ------------- ------------- --------------
Loss per share attributable to
the equity holders of the Company
Basic and diluted loss per ordinary
share 6 (0.042)p (0.32)p (0.52)p
-------------------------------------------- ------- ------------- ------------- --------------
STATEMENT OF FINANCIAL POSITION (UNAUDITED)
AS AT 30 JUNE 2021
30 June 30 June 31 December
2021 2020 2020
Notes Unaudited Unaudited Audited
GBP GBP GBP
------------------------------- ------ ------------- ------------- -------------
ASSETS
Non-current assets
Intangible assets 77,294 94,110 83,763
Property, plant and equipment 112,645 122,870 114,145
Right of use assets 15,037 112,760 49,404
Total non-current assets 204,976 329,740 247,312
------------------------------- ------ ------------- ------------- -------------
Current assets
Inventories 9 377,156 565,114 569,589
Trade and other receivables 10 524,049 303,510 173,871
Corporation tax receivable 218,568 - 218,568
Cash and cash equivalents 4,483,252 1,534,563 397,069
Total current assets 5,603,025 2,403,187 1,359,097
------------------------------- ------ ------------- ------------- -------------
TOTAL ASSETS 5,808,001 2,732,927 1,606,409
------------------------------- ------ ------------- ------------- -------------
EQUITY AND LIABILITIES
Equity
Share capital 11 1,702,913 1,140,913 1,140,913
Share premium 12 28,006,018 24,867,886 24,867,886
Share-based payment reserve 13 2,743,064 438,509 324,264
Retained losses (27,002,762) (24,332,442) (25,090,083)
Total Equity 5,449,233 2,114,866 1,242,980
------------------------------- ------ ------------- ------------- -------------
Current liabilities
Trade and other payables 14 245,346 339,743 185,927
Lease liability 16,143 - 52,370
Total current liabilities 261,489 339,743 238,297
------------------------------- ------ ------------- ------------- -------------
Non-current liabilities
Provisions 15 97,279 159,030 124,035
Lease Liability - 119,288 1,097
Total non-current liabilities 97,279 278,318 125,132
------------------------------- ------ ------------- ------------- -------------
Total liabilities 358,768 618,061 363,429
------------------------------- ------ ------------- ------------- -------------
TOTAL EQUITY AND LIABILITIES 5,808,001 2,732,927 1,606,409
------------------------------- ------ ------------- ------------- -------------
STATEMENT OF CHANGES IN EQUITY (UNAUDITED)
AS AT 30 JUNE 2021
Share
based-
Share Share payment Retained Total
Notes capital premium reserve Losses equity
GBP GBP GBP GBP GBP
--------------------- ------ ----------------- ------------------- ------------------ -------------------- -----------------
At 1 January 2020 1,140,913 24,867,886 412,539 (22,857,941) 3,563,397
Total comprehensive
loss for
the period - - - (1,479,949) (1,479,949)
Transactions with
owners:
Transfer in respect
of lapsed
share options - - (5,448) 5,448 -
Share-based
payments-share
options - - 31,418 - 31,418
At 30 June 2020
(unaudited) 1,140,913 24,867,886 438,509 (24,332,442) 2,114,866
--------------------- ------ ----------------- ------------------- ------------------ -------------------- -----------------
At 1 January 2020 1,140,913 24,867,886 412,539 (22,857,941) 3,563,397
Total comprehensive
loss for
the year - - - (2,372,658) (2,372,658)
Transactions with
owners:
Transfer in respect
of lapsed/forfeited
share options - - (140,516) 140,516 -
Share-based
payments-share
options - - 52,241 - 52,241
At 31 December 2020
(audited) 1,140,913 24,867,886 324,264 (25,090,083) 1,242,980
--------------------- ------ ----------------- ------------------- ------------------ -------------------- -----------------
At 1 January 2021 1,140,913 24,867,886 324,264 (25,090,083) 1,242,980
Total comprehensive
loss for
the period - - - (2,106,925) (2,106,925)
Transactions with
owners:
Shares issued 11/12 562,000 5,058,000 - - 5,620,000
Share issue costs 11/12 - (1,919,868) 1,503,008 - (416,860)
Transfer in respect
of
cancelled/forfeited
share options - - (194,246) 194,246 -
Share based
payments-share
options - - 1,110,038 - 1,110,038
At 30 June 2021
(unaudited) 1,702,913 28,006,018 2,743,064 (27,002,762) 5,449,233
--------------------- ------ ----------------- ------------------- ------------------ -------------------- -----------------
STATEMENT OF CASH FLOWS (UNAUDITED)
FOR THE SIX MONTHSED 30 JUNE 2021
6 months 6 months Year to
to 30 to 30 June 31 December
June 2021 2020 2020
Notes Unaudited Unaudited Audited
GBP GBP GBP
------------ -------------------- -------------
Total comprehensive loss for the
period (2,106,925) (1,479,949) (2,372,658)
Amortisation of intangible assets 20,133 20,818 40,767
Depreciation of right of use assets 34,367 45,156 87,237
Depreciation of property, plant
and equipment 39,222 40,457 80,034
Transfer of property, plant and 23,867 - -
equipment to cost of goods
Profit on disposal of right of use
assets - - (1,426)
Decrease in provision for warranty (26,756) (2,071) (12,713)
(Decrease)/Increase in provision
for expected credit losses (18,532) 8,059 64,281
Provision for redundancy - 24,353 -
Share-based payments 1,110,038 31,418 52,241
(Decrease)/Increase in inventory
provision (10,442) - 17,650
Tax on loss on ordinary activities - 857 (217,711)
Interest on lease liability 1,554 5,492 9,041
Interest received (2,983) (4,359) (4,393)
Fees shares issued 47,664 - -
Accrued furlough income - - (17,748)
Decrease/(Increase) in inventories 202,883 (178,873) (200,998)
(Increase)/Decrease in trade and
other receivables (298,503) 118,672 209,838
Increase/(Decrease) in trade and
other payables 59,419 49,180 (104,636)
------------ -------------------- -------------
Cash used in operations (924,994) (1,320,790) (2,371,194)
Corporation tax received - 321,585 321,584
Net cash used in operating activities (924,994) (999,205) (2,049,610)
------------------------------------------------- ------------ -------------------- -------------
Cash flows from investing activities
Purchases of intangible assets (13,664) (17,717) (27,319)
Purchases of property, plant and
equipment (39,493) (38,600) (69,452)
Interest received 2,325 20,072 20,106
Net cash used in investing activities (50,832) (36,245) (76,665)
------------------------------------------------- ------------ -------------------- -------------
Cash flows from financing activities
Proceeds from share issues 5,500,000 - -
Share issue costs (416,860) - -
Furlough grant income received 17,748 - -
Payments relating to lease commitments (38,879) (50,745) (97,414)
Net cash from/(used in) financing
activities 5,062,009 (50,745) (97,414)
------------------------------------------------- ------------ -------------------- -------------
Net increase/(decrease) in cash
and cash equivalents 4,086,183 (1,086,195) (2,223,689)
Cash and cash equivalents at beginning
of the year 397,069 2,620,758 2,620,758
Cash and cash equivalents at the
end of the period 4,483,252 1,534,563 397,069
------------------------------------------------- ------------ -------------------- -------------
NOTES TO THE INTERIM FINANCIAL INFORMATION (UNAUDITED)
1. Nature of Operations
Microsaic Systems plc (the "Company") is registered in England
and Wales. The Company's registered office is GMS House, Boundary
Road, Woking, GU21 5BX. The Company has no subsidiaries, so the
financial information relates to the Company only. Microsaic is a
high technology company developing compact, chip-based mass
spectrometers that are designed to improve the efficiency of
pharmaceutical R&D.
2. General Information
The interim financial information has been prepared in
accordance with international accounting standards in conformity
with the requirements of the Companies Act 2006. The accounting
policies, methods of computation and presentation used in the
preparation of the interim financial information are the same as
those used in the Company's audited financial statements for the
year ended 31 December 2020.
The interim financial information in this statement does not
constitute full statutory accounts as defined by Section 434 of the
Companies Act 2006 and has not been audited.
The interim financial information for the six months to 30 June
2021 has been prepared using extracts from the financial statements
prepared for the year ended 31 December 2020. Those financial
statements have been filed with the Registrar of Companies. The
auditor's report on those financial statements was unqualified.
3. Basis of preparation
The financial statements are presented in GB Pounds Sterling.
The financial information has been prepared on the historical cost
basis, except where financial instruments are required to be
carried at fair value under IFRS. The financial information has
been prepared on a going concern basis.
4. Restated figures for H1 2020
The COVID-19 furlough grant from the Government was reported as
a reduction in employment costs at 30 June 2020. At 31 December
2020 the furlough grant was treated as other operating income.
Therefore, to be consistent with the treatment adopted at the year
end the figures for the 6 months to 30 June 2020 have been
restated. Other operating income has been restated from nil to
GBP40,324 and operating expenses has been increased by GBP40,324 to
GBP1,524,988. In addition, at 31 December 2020 professional fees
related to one-off corporate transactions were shown separately on
the face of the statement of comprehensive income. For consistency
purposes this treatment has been adopted for the 6 months ended 30
June 2020 and GBP39,036 has been shown separately on the face of
the statement of comprehensive income.
5. Revenues
Throughout H1 2021, the Company operated in one business
segment, that of research, development and commercialisation of
mass spectrometry instruments. The attribution of revenue is based
on the country or group of countries to where the goods are
shipped. Our largest customer represented 33.9% of total revenue in
H1 2021 (H1 2020: 54.5%) and our second largest customer
represented 15.5% of total revenue (H1 2020: 13.1%).
The geographical analysis of revenues (by location of shipment)
was as follows:
6 months 6 months Year to
to 30 June to 30 June 31 December
2021 2020 2020
Unaudited Unaudited Audited
GBP GBP GBP
--------------- ------------ ------------ -------------
UK 220,192 - 2,225
Japan - 8,756 8,756
USA 130,960 38,796 41,346
Europe 42,057 21,335 57,280
China 106,076 - 126
South Korea - - 83,397
Rest of World - 3,105 5,128
--------------- ------------ ------------ -------------
499,285 71,992 198,258
--------------- ------------ ------------ -------------
Revenue by Product Group:
Product/Unit 367,474 - 83,397
Consumables and spares 119,641 66,766 105,135
Service and support income 12,170 5,226 9,726
499,285 71,992 198,258
---------------------------- -------- ------- --------
6. Loss per share
6 months 6 months Year to
to 30 June to 30 June 31
2021 2020 December
Unaudited Unaudited 2020
Audited
------------------------------------- --------------- ------------- --------------------
Comprehensive loss attributable
to equity shareholders (GBP) (2,106,925) (1,479,949) (2,372,658)
Weighted average number of ordinary
0.01p (2020: 0.25p) shares for
the purpose of basic and diluted
loss per share 4,989,624,815 456,365,146 456,365,146
Basic and diluted loss per ordinary
share (0.042)p (0.32)p (0.52)p
-------------------------------------- --------------- ------------- --------------------
The basic loss per share of 0.042p is significantly below last
year (H1 2020: 0.32p per share) mainly due to the issue of 5.62
billion shares at the time of the fundraise in February 2021.
Potential ordinary shares are not treated as dilutive as the
Company is loss making, therefore the weighted average number of
ordinary shares for the purposes of the basic and diluted loss per
share are the same.
7. EBITDA Adjusted Loss
A key indicator of performance for the Company in 2021 is EBITDA
Adjusted Loss (Loss of earnings before interest, tax, depreciation,
amortisation and other items such as share-based payments and
exceptional one-off expenditure). Detailed below is the EBITDA
Adjusted Loss for the period:
6 months 6 months Year to
to 30 June to 30 June 31 December
2021 2020 2020
Unaudited Unaudited Unaudited
RESTATED
GBP GBP GBP
------------------------------------ ------------ ------------ ------------
Comprehensive loss for period (2,106,925) (1,479,949) (2,372,658)
Adjust for:
Tax on loss on ordinary activities - 857 (217,711)
Depreciation of property, plant
and equipment 39,222 40,457 80,034
Depreciation of right of use
assets 34,368 45,156 87,237
Amortisation of Intangibles 20,133 20,818 40,767
Net finance cost (1,429) 1,305 6,382
Share-based payments 1,110,038 31,418 52,241
Exceptional costs 65,789 39,036 149,364
------------------------------------ ------------ ------------ ------------
EBITDA Adjusted Loss (838,804) (1,300,902) (2,174,344)
------------------------------------ ------------ ------------ ------------
8. Employees and employment related costs
6 months 6 months Year to
to 30 June to 30 June 31 December
2021 2020 2020
Unaudited Unaudited Audited
Staff Numbers RESTATED
------------ ------------ -------------
Directors 4 5 5
Other staff 17 22 21
Average Headcount 21 27 26
-------------------------------- ------------ ------------ -------------
GBP GBP GBP
-------------------------------- ------------ ------------ -------------
Employment costs (including
Directors)
Wages and salaries 590,195 627,586 1,081,201
Social security costs 67,452 58,224 121,141
Termination payments - 24,353 58,283
Pension costs 80,296 86,769 153,476
Employment related share-based
payments 1,110,038 31,418 52,241
-------------------------------- ------------ ------------ -------------
1,847,981 828,350 1,466,342
-------------------------------- ------------ ------------ -------------
The 6 months to 30 June 2020 figures have been restated to
reflect the furlough grant income (GBP40,324) as other operating
income rather than a reduction in employment costs. This treatment
is consistent with the audited figures for the year ended 31
December 2020.
9. Inventories
30 June 30 June 31 December
2021 2020 2020
Unaudited Unaudited Audited
GBP GBP GBP
--------------------------- ---------------------------------- ---------- -------------------------
Raw materials 235,904 268,292 262,506
Work in progress - 7,616 -
Finished goods 188,413 329,160 364,687
---------------------------
Subtotal 424,317 605,068 627,193
--------------------------- ---------------------------------- ---------- -------------------------
Provision for inventories (47,161) (39,954) (57,604)
Total 377,156 565,114 569,589
--------------------------- ---------------------------------- ---------- -------------------------
Inventories reduced significantly from the balance at the 30
June 2020 and 31 December 2020 due to a recovery in sales during H1
2021.
10. Trade and other receivables
30 June 30 June 31 December
2021 2020 2020
Unaudited Unaudited Audited
GBP GBP GBP
-------------------------------- --------- --------- ------------------
Amounts falling due within one
year
Trade receivables 348,722 94,490 108,529
Provision for expected credit
losses (30,977) (12,365) (68,587)
Other receivables 206,304 209,681 123,385
Other taxes - 11,704 10,544
524,049 303,510 173,871
-------------------------------- --------- --------- --------------------
Trade receivables are significantly above both 30 June 2020 and
31 December 2020 as a result of higher sales in H1 2021 and
particularly in June 2021. The overdue balance at 30 June 2021
relates to the same customer outstanding at the 31 December 2020.
The reduction in the balance for this customer from GBP68,174 to
GBP27,000 reflects the recovery of one of the units sold and a part
write-off of the outstanding balance.
11. Share capital
31 December
30 June 2021 30 June 2020 2020
Unaudited Unaudited Audited
GBP GBP GBP
---------------------------- ------------ -------------- -----------
Allotted, issued and fully
paid Ordinary shares
of 0.01p each (2020: 0.25p
each):
Opening balance 1,140,913 1,140,913 1,140,913
Shares issued in the period 562,000 - -
---------------------------- ------------ -------------- -----------
Closing balance 1,702,913 1,140,913 1,140,913
---------------------------- ------------ -------------- -----------
On 5 February 2021 the Company undertook a share reorganisation
reducing the nominal value of ordinary shares from 0.25p to 0.01p
per share. Part of the share reorganisation involved the creation
of deferred shares with a nominal value of 0.24p per share. Each
deferred share will have very limited rights and will effectively
be valueless. Also, on 5 February 2021 5,620,000,000 ordinary
shares were issued for cash and services. The nominal value of
these shares amounted to GBP562,000. The nominal value of the
ordinary shares is GBP607,637. Deferred shares of 456,365,146 have
a nominal value of GBP1,095,276. The number of ordinary shares in
issue at the period end is 6,076,365,146 (2020: 456,365,146).
12. Share Premium
30 June 30 June 31 December
2021 2020 2020
Unaudited Unaudited Audited
GBP GBP GBP
------------------------------------- --------------- ----------- -----------
Opening balance 24,867,886 24,867,886 24,867,886
Shares issued in the period 5,058,000 - -
Share issue costs - Cash (416,860) - -
Share issue costs - Broker Warrants (1,503,008) - -
------------------------------------- --------------- ----------- -----------
Closing balance 28,006,018 24,867,886 24,867,886
------------------------------------- --------------- ----------- -----------
The fundraising on 5 February 2021 raised a total of GBP5.5
million (before expenses) at a placing price of 0.1p per share. The
placing raised GBP5 million and the broker warrant GBP0.5 million,
before expenses. The share premium on the fundraising was the
placing price of 0.1p per share less the nominal value of 0.01p per
share multiplied by the number of shares issued. The cash costs
amounted to GBP416,860 including broker commissions and fees, legal
fees etc. In addition, 997,000,000 broker warrants were issued to
Turner Pope Investments (TPI) Ltd at a fair value of
GBP1,503,008.
13. Share-based Payments Reserve
Options Warrants Total (Unaudited)
GBP GBP GBP
----------------------------- ---------- ---------- ------------------
Balance at 1 January 2021 324,264 - 324,264
Broker Warrants issued - 1,503,008 1,503,008
Share-based payments charge 1,110,038 - 1,110,038
Forfeited/Cancelled options (194,246) - (194,246)
Balance at 30 June 2021 1,240,056 1,503,008 2,743,064
----------------------------- ---------- ---------- ------------------
14. Trade and other payables
30 June 30 June 31
2021 2020 December
2020
Unaudited Unaudited Audited
GBP GBP GBP
-------------------------------------- ---------- ---------- ----------
Amounts falling due within one year:
Trade payables 80,692 141,930 63,034
Other taxes and social security 37,558 31,960 29,174
Other payables 31,231 13,491 11,278
Accruals and deferred income 95,865 152,362 82,441
-------------------------------------- ---------- ---------- ----------
245,346 339,743 185,927
-------------------------------------- ---------- ---------- ----------
Total trade and other payables at 30 June 2021 are GBP94,397
below 30 June 2020, but GBP59,419 above 31 December 2020 balance.
Other payables at 30 June 2021 included VAT of GBP15,976.
15. Provisions
Dilapidations Warranty Total unaudited
GBP GBP GBP
--------------------------------- -------------- --------- ----------------
Balance at 1 January 2021 75,779 48,256 124,035
Charges against provisions - - -
Provided for/(Reduction) during
the period - (26,756) (26,756)
Balance at 30 June 2021 75,779 21,500 97,279
--------------------------------- -------------- --------- ----------------
The dilapidations provision remains unchanged from 31 December
2020 balance. The warranty provision methodology was updated to
more closely reflect those MS products under warranty and takes
into account the Company's historically low incidence of warranty
claims.
16. Share options
The Company operates an Enterprise Management Incentive ("EMI")
scheme and an Unapproved Share Option scheme as a means of
encouraging ownership and aligning interests of staff and
shareholders. The table below shows the number of options
outstanding and exercisable at 30 June 2021 and the weighted
average exercise price.
6 months to 30 June 6 months to 30 Year to 31 December
2021 June 2020 2020
Unaudited Unaudited Audited
Number of Weighted Number Weighted Number Weighted
options average of options average of options average
exercise exercise exercise
price price price
---------------- ---------- ------------- ---------- -------------- ------------
Outstanding
at the beginning
of the year 17,475,000 5.1p 18,644,000 5.2p 18,644,000 5.2p
---------------- ---------- ------------- ---------- -------------- ------------
Granted during
the period 1,125,000,000 0.1p - - - -
---------------- ---------- ------------- ---------- -------------- ------------
Forfeited/Cancelled
during the period (17,475,000) 5.1p (240,000) 10.8p (1,169,000) 6.0p
---------------- ---------- ------------- ---------- -------------- ------------
Exercised during
the period - - - - - -
---------------- ---------- ------------- ---------- -------------- ------------
Outstanding
at period end 1,125,000,000 0.1p 18,404,000 5.1p 17,475,000 5.1p
---------------- ---------- ------------- ---------- -------------- ------------
Exercisable
at period end 750,000,000 0.1p 2,804,000 13.3p 4,375,000 9.8p
---------------- ---------- ------------- ---------- -------------- ------------
Options amounting to 1.125 billion ordinary shares were awarded
to Directors, staff and a consultant on 5 February 2021, at the
time of the fundraising. Staff and Directors agreed to cancel
existing options prior to the award of new options as these options
were all out-of-the-money. The new options granted are exercisable
at the placing price of 0.1p for five years from the 5 February
2021. 750 million options granted to Directors and a consultant
vested during the period as the performance criterion that the
Company's ordinary shares traded at a VWAP at or above a 50 per
cent. premium to the placing price for 20 consecutive business
days, was achieved. The staff options are exercisable two years
from the date of grant as long as the optionee is still an employee
of the Company.
17. Warrants
Broker warrants to subscribe for up to 997,000,000 ordinary
shares, which represented 20 per cent of the placing shares, were
granted to Turner Pope Investments (TPI) Ltd as part of the
fundraising on 5 February 2021. The broker warrants are capable of
exercise for a period of two years from 5 February 2021. The fair
market value of the warrants was calculated at GBP1,503,008.
18. Commitments
As at 30 June 2021, purchase commitments with our manufacturing
supplier for mass spectrometry materials, parts and components
contracted for but not included in the financial statements
amounted to GBP367,173 (31 December 2020: GBP426,595).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IR DKQBQABKDNCB
(END) Dow Jones Newswires
September 27, 2021 02:00 ET (06:00 GMT)
Microsaic Systems (LSE:MSYS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Microsaic Systems (LSE:MSYS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024